Abcuro raises $66 million to launch Phase 3 trial in muscle-weakening disease after earlier setback

Abcuro announced it has secured $66 million in financing to support a Phase 3 clinical study targeting a muscle-weakening condition.

The funding comes after the company previously reported that its lead candidate did not meet primary endpoints in an earlier trial.

Researchers now believe the drug may be effective in a subset of patients with milder forms of the disease, prompting the decision to move forward with a larger study.

The capital raise will be used to fund the upcoming trial and related development activities, positioning Abcuro to further evaluate the therapeutic potential of its candidate.